AI-driven digital platforms accelerate education and adoption of newly implemented treatment guideline recommendations.

Abstract

e13671 Background: Advances in Research continually drive improvements in patient care, with numerous breakthroughs driving updates to clinical guidelines. However, a significant challenge lies not only in communicating these cutting-edge advancements but also in educating physicians and patients about their value and driving their adoption into clinical practice. In this study we evaluated the knowledge and adoption gaps of a newly added treatment guideline in a cohort of prostate cancer (PC) patients (pts) searching for treatment options using an AI-based digital platform and the impact of personalized education provided to the pts on the platform. Methods: The analysis was performed on a cohort of 103 newly diagnosed intermediate-risk prostate cancer (irPC) pts recommended for screening with MRI-guided biopsy (MRIGB). MRIGB was added to national guidelines as a recommended procedure in March 2023 We evaluated knowledge levels, conversion rates following educational interventions, and potential barriers to information access. This analysis utilized data from Leal Health, an AI-driven direct-to-patient treatment decision support platform. Results: Out of 103 irPC pts recommended for MRIGB, only 18 (19.4%) underwent the procedure, with no notable differences in baseline characteristics (e.g., age, race or gleason score). Pts who did not go through MRIGB had no knowledge of the procedure, with the majority having previously undergone standard transrectal ultrasound-guided biopsy (TRUS). 70.3% of patients were affiliated to community centers (CC) and 29.7% were treated at Academic Medical Centers (AMC). A profound effect was observed based on the medical facility where pts were treated. 47% of pts affiliated with AMC underwent MRIGB, compared to only 16% at CC (p < 0.0001). Of the 79 pts who lacked prior knowledge of MRIGB, their education resulted in immediate adoption of the procedure in 5% of pts. Patients who opted out of immediately moving forward with MRIGB cited concerns about invasiveness and need for additional biopsies (54.5%), lack of nearby facilities (10.9%), preference for alternative non-invasive treatments (10.9%), physician recommendation (5.5%), and insurance constraints (3.6%) as the main reason for their decision. Conclusions: Despite the proven clinical benefits of newly added treatments to clinical guidelines, many eligible patients remain unaware of these options for extended periods. Limited access to knowledge, particularly in community settings, poses a significant challenge. AI-driven digital platforms such as Leal address this gap by delivering personalized treatment plans accessible education, empowering patients to make informed decisions about their care. The AI platform can expedite adaption of innovative treatments, driving their integration into practice and ultimately improving outcomes.